论文部分内容阅读
安进公司宣布首个治疗偏头痛Ⅲ期临床新药厄瑞奴单抗(erenumab)试验达到主终点。与安慰剂比较,较基线明显减少阵发性偏头痛每月发作的天数。该药靶向和阻断降钙素基因相关肽受体,此受体与偏头痛发作有关。ARISE研究是全球范围的Ⅲ期临床试验,为多中心、随机、12周、双盲、安慰剂对照研究,评价该药对预防阵发性偏头痛的疗效和安全性。577名患者按1∶1随机接受该药70 mg或安慰剂皮下注射,1次/
Amgen announced the first endpoint of the first clinical trial of migraine III, a new clinical drug, erenumab. Compared with placebo, the number of days of paroxysmal migraine attacks per month was significantly reduced from baseline. This drug targets and blocks the calcitonin gene-related peptide receptor, which is associated with migraine attacks. The ARISE study is a worldwide Phase III clinical trial evaluating the efficacy and safety of the drug in the prevention of paroxysmal migraine for a multicenter, randomized, 12-week, double-blind, placebo-controlled study. 577 patients were randomized to receive either a 1 mg / day dose of 70 mg or a placebo subcutaneously at 1: